Bryostatin 1 in Non-Hodgkin's Lymphoma Patients
Author Information
Author(s): Blackhall F H, Ranson M, Radford J A, Hancock B W, Soukop M, McGown A T, Robbins A, Halbert G, G C Jayson
Primary Institution: Cancer Research Campaign
Hypothesis
Does bryostatin 1 have efficacy in treating non-Hodgkin's lymphoma?
Conclusion
The study found that bryostatin 1 did not demonstrate efficacy in treating non-Hodgkin's lymphoma.
Supporting Evidence
- In 14 evaluable patients, no responses were seen.
- Stable disease was attained in one patient for 9 months.
- The principal toxicities were myalgia and phlebitis.
- Treatment was discontinued early in some patients due to toxicity.
Takeaway
The study tested a drug called bryostatin 1 on people with a type of cancer, but it didn't work well.
Methodology
Patients received a median of 6 intravenous infusions of bryostatin 1 once weekly.
Limitations
The study had a small sample size and treatment was discontinued early due to toxicity.
Participant Demographics
Patients had progressive non-Hodgkin's lymphoma of indolent type and were previously treated with chemotherapy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website